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Abstract
Background: Reduced choroidal perfusion is hypothesized to play a role in the pathogenesis of
normal tension glaucoma. Thus the impact of antiglaucomatous eye drops on ocular perfusion has
been the focus of recent research and the subject of intensive investigations. The present study
investigates whether topically applied latanoprost or bimatoprost influence ocular perfusion in
patients with normal tension glaucoma and compares these effects with that changes detected after
the treatment with dorzolamide.
Methods: Ocular hemodynamics were assessed by color Doppler imaging (CDI) shortly before
and after a one-month treatment with either latanoprost, bimatoprost or dorzolamide. Primary
end-points of the study were peak systolic and end-diastolic blood flow velocities in the short
posterior ciliary artery (SPCA) under the new therapy. Intraocular pressure (IOP) and additional
perfusion parameters in the SPCA and other retrobulbar vessels were tracked as observational
parameters. n = 42 patients with normal tension glaucoma were enrolled in the study.
Results: Systolic and diastolic blood flow velocities in the SPCA showed no significant alteration
after the treatment with latanoprost or bimatoprost. Dorzolamide lead to increase of peak systolic
velocity. IOP was reduced by all three agents in a range reported in the literature.
Conclusion: Topically applied latanoprost and bimatoprost act in a hemodynamically neutral
manner and have the capability to lower IOP even in patients with normal tension glaucoma and
low initial IOP level. Dorzolamide accelerates blood flow in systole. None of the tested compounds
has a negative impact on hemodynamics in the short posterior ciliary arteries.
Background
Traditionally atrophy of the optic nerve head in glaucoma
patients has been related to a chronically increased
intraocular pressure (IOP).[1] In the majority of glau-
coma patients increased IOP levels can be measured. At
the same time there is a significant number of patients
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who develop the major features of glaucoma, meaning
progressive visual field loss and atrophy of the optic nerve
head, although the IOP is in the normal range below 21
mmHg in these individuals. [2-6] This variant of primary
open angle glaucoma has been termed as normal tension
glaucoma and the glaucomatous changes have been – at
least in part – attributed to reduced perfusion of the optic
nerve head by different authors. [6-8] Thus patients with
normal tension glaucoma constitute a particularly inter-
esting group for investigating pharmacological effects on
ocular perfusion.
Up to now therapy of normal tension glaucoma does not
differ substantially from the therapy of classical primary
open angle glaucoma with increased IOP level: in both
cases the focus is set on lowering IOP.[9,10] There is a ten-
dency for defining lower target IOPs individually for each
patient and optimizing ocular hemodynamics is still rated
as complementary. Recently, several systemic approaches
have been evaluated, e.g. oral administration of magne-
sium or the calcium antagonist nimodipine.[11,12] In
addition, the hemodynamic effects of locally applied
antiglaucomatous drugs are subject to intensive investiga-
tions within the last years: [13-16] Dorzolamide, an
inhibitor of the carbonic anhydrase has shown the most
promising effects on ocular hemodynamics. [17-19] In
contrast, brinzolamide did not to alter ocular per-
fusion.[20] ß-receptor antagonists influence parameters
of ocular hemodynamics differently depending on the
compound used: betaxolol and carteolol lower vascular
resistance while timolol seems to lead to an increased vas-
cular tone.[15] The α 2-receptor agonist brimonidine did
not affect ocular perfusion in primary open angle glau-
coma patients.[21] Derivatives of prostaglandins have
become more and more popular for the treatment of glau-
coma patients since they are very effective in lowering IOP
and have to be applied only once a day.[22] Up to now
there are predominantly four substances in clinical use:
latanoprost, bimatoprost, travoprost and unoprostone.
Only few studies have addressed the influence of prostag-
landin analogues on ocular perfusion so far.
Prostaglandins constitute a large group of compounds
produced endogenously with various and partially con-
trary effects on vascular tone.[23,24] Certain prostagland-
ins, such as PGI2 and PGE2, are potent vasodilators; others
like PGF2α  constricts arteries. [25-27] Investigations of the
vasoactive effects of prostaglandins are complicated by the
species dependency of their effects on vascular tone.[28]
Latanoprost derives from PGF2α  and has been reported to
improve the perfusion of the optic nerve head[13],
although in vitro studies indicate that latanoprost in con-
trast to its chemical origin PGF2α  exerts no or minimal
effects on vascular tone in the primate eye.[28] Bimato-
prost has been demonstrated to have a vasoconstricting
effect on isolated porcine ciliary arteries in vitro.[29] It is
unknown whether this effect is of relevance in vivo and in
humans.
The aim of the present study is to compare the hemody-
namic effects of bimatoprost and latanoprost in patients
with normal tension glaucoma. The effects were com-
pared with the hemodynamic properties of dorzolamide,
which has repeatedly been shown to improve ocular
blood flow and can therefore be used as a reference com-
pound for the evaluation of hemodynamic effects of
antiglaucomatous eye drops. [17-19] It is hypothesized
that these compounds lead to changes in systolic and
diastolic blood flow velocities within the short posterior
cilary artery. This vessel constitutes the main blood supply
to the optic nerve head and alterations in its perfusion
might play an important role in the pathogenesis and pro-
gression of normal tension glaucoma.
Methods
The study was performed in accordance to institutional,
national, and international guidelines and was approved
by the local ethics committee. The study was designed as
an interventional, randomized, prospective, institutional,
single-blinded, controlled, clinical trial.
Color Doppler imaging
Color Doppler imaging (CDI) was performed with a
Sonoline Elegra Advanced System (Siemens, Erlangen,
Germany) using a phased array transducer type 7.5L40
(Siemens, Erlangen, Germany) as described previ-
ously.[30] Ultrasound frequency was 6.5 MHz in the
pulsed Doppler mode. The transducer was carefully set on
the closed eye lid without exerting pressure on the bulb.
Acoustic coupling between transducer and skin was opti-
mized by a carbomeric gel (Vidisic®, Dr. Mann Pharma,
Germany). After identification of the optic nerve as a land-
mark the following vessels were investigated in the color
Doppler mode: central retinal artery (CRA), short and
long posterior ciliary arteries (SPCA and LPCA) and oph-
thalmic artery (OA). Blood flow in the CRA was measured
along its course through the optic nerve. Velocities in the
SPCA and LPCA were recorded before entering the sclera.
Flow velocity in the OA was measured close to its crossing
of the optic nerve. The angle between transducer and ori-
entation of the vessel was corrected. Gain and threshold
were adjusted individually for each examination until
noise disappeared and then kept constant during the
entire examination. Pulse repetition frequency (PRF) was
minimized to avoid aliasing (typically 5208 Hz for the
OA, and 2500 Hz for the SPCA and LPCA in the Doppler
mode). Sample size for all vessels was set constantly to 1.5
mm.BMC Ophthalmology 2005, 5:6 http://www.biomedcentral.com/1471-2415/5/6
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The changes of blood flow velocities over the course of a
cardiac cycle were recorded continuously. Peak systolic
velocity (PSV) and end diastolic velocity (EDV) can be
determined directly and pulsatility index (PI) and resistive
index (RI) are calculated automatically by the CDI
software.
Patients
Consecutive patients with progressive normal tension
glaucoma were randomized either to the latanoprost or to
the bimatoprost group. Progression was defined as pro-
gressive excavation of the optic disc (funduscopic and
controlled by the Heidelberg retina tomography – HRT)
and/or progressive visual field loss in the Humphrey
perimeter over the last 6–12 months. Glaucoma progres-
sion was assessed by the same glaucoma specialist (M.K.)
in all patients. The patients underwent CDI measurements
of ocular perfusion of the right eye by CDI shortly before
and 3 to 5 weeks after initiation a local therapy with either
latanoprost or bimatoprost. Both eye drops were applied
once a day between 6 p.m. and 8 p.m. Normal tension
glaucoma patients with unchanged excavation of the optic
disc in funduscopy and HRT as well as stable visual field
over the last 6–12 months served as negative controls. The
glaucoma parameters in the control group were assessed
by the same glaucoma specialist (M.K.) like in the therapy
group. In the control group two subsequent CDI examina-
tions were performed with an interval of 3 to 5 weeks. An
additional group of patients with progressive normal ten-
sion glaucoma received dorzolamide eye drops three
times a day, which has been reported to enhance blood
flow in retrobulbar vessels. [17-19] This group was
recruited to demonstrate that the CDI-methodology used
is suitable to detect changes in retrobulbar blood flow.
Regarding the assessment of progression the same criteria
were applied as for the other study groups. CDI-examina-
tions in the dorzolamide group were carried out shortly
before and 3 to 5 weeks after initiation of the dorzolamide
therapy.
All measurements in both therapy and control groups
were carried out at 4 p.m. ± 2 h as a standardized time
point to ensure best possible comparability. This specific
time point was chosen due to organizational reasons.
Prior to CDI intraocular pressure was measured. All exam-
inations were performed with the patient sitting in an
upright position and all the patients rested for several
minutes before the examination started. CDI measure-
ments for this study were performed by two experienced
investigators (O.Z. and E.T.M.). To exclude investigator
dependent effects, both CDI measurements in one patient
were performed by the same physician. The study group
membership and the individual therapy of the patients
were masked for the CDI-investigator.
Patients with an intraocular pressure higher than 21
mmHg prior to therapy as well as patients with cardiovas-
cular diseases were not included in the study. Systemic
medication of the patients did not change between their
first and second presentation. Patients who had ophthal-
mic surgery to the right eye were excluded from the study.
Bimatoprost
Lumigan® eye drops from Pharm Allergan (Ettlingen, Ger-
many) were used in the bimatoprost treatment group.
Lumigan® contains 0.3 mg/ml bimatoprost. The solvent
contained benz alkonium chloride, sodium chloride, di
sodium hydrogene phosphate 7H2O, citric acid, hydro-
chloric acid or sodium hydroxide (for pH adjustment),
and water.
Latanoprost
Latanoprost (50 µg/ml) was obtained from Pharmacia
Pfizer (Karlsruhe, Germany) as Xalatan®. Further ingredi-
ents are benz alkonium chloride, sodium chloride,
sodium dihydrogene phosphate 1H2O, sodium monohy-
drogene phosphate, and water.
Dorzolamide
Dorzolamide was obtained in form of Trusopt®  from
MSD-Chibret, Munich, Germany. Trusopt®  containes
22.26 mg dorzolamide hydrochloride per 1 ml. Further
ingredients of Trusopt® are hydroxyethylcellulose, D-man-
nitole, sodium citrate, sodium hydroxide, benzalkonium
chloride and water as solvent.
Statistics
Statistical analysis of the data was done with SPSS 10.0.
All data are given as mean ± standard error of means
(SEM). Student's t-test for paired data was used. It was
hypothesized that the tested compounds would influence
peak systolic and end-diastolic blood flow velocities (PSV
and EDV) in the short posterior ciliary artery (SPCA). Thus
two statistical tests were performed in each of the four
study groups resulting in eight parallel statistical tests in
total. Performing multiple statistical tests in a study neces-
sitates the correction of the P-value to reach a significance
level of 0.05. Therefore the Bonferroni-adjustment was
applied and P < 0.006 is considered to be significant (dou-
ble sided). All other parameters except EDV and PSV in
SPCA were evaluated in a descriptive manner. Thus no P-
values will be presented for these observational
parameters.
In an a-priori-power-analysis the sample size was calcu-
lated. H1 was defined by an increase of flow velocity by
50% and a standard deviation of 35%. This definition was
applied because preliminary data indicated a change in
that range caused by dorzolamide. To reach a statistic
power of 0.80 or more at least n = 9 individuals for PSVBMC Ophthalmology 2005, 5:6 http://www.biomedcentral.com/1471-2415/5/6
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and n = 8 individuals for EDV per treatment group are
required. For power analysis, the tool G*POWER V. 2.0 of
F. Faul and E. Erdfelder [31] was applied.
Results
11 patients were treated with bimatoprost, 10 patients
with latanoprost. Initially 9 patients were enrolled in the
negative control group, but only 8 could be evaluated.
One patient had to be excluded, because he did not return
to the second examination due to personal reasons. 12
additional patients received dorzolamide. All data shown
was obtained from measurements of the right eye of the
patients.
Intraocular pressure (IOP)
Intraocular pressure was reduced from 14.6 ± 1.7 to 11.4
± 0.8 mmHg under therapy with bimatoprost; latanoprost
led to a decrease from 14.8 ± 2.2 to 12.3 ± 1.5 mmHg.
Dorzolamide decreased the IOP in the dorzolamide group
from 16.8 ± 1.6 to 14.8 ± 0.9 mmHg. In the negative con-
trol group intraocular pressure was 13.2 ± 1.7 mmHg at
first presentation and 12.5 ± 1.9 mmHg at second presen-
tation 3 to 5 weeks later (fig. 1).
Color Doppler imaging (CDI)
Neither bimatoprost nor latanoprost showed a statisti-
cally significant influence on peak systolic or enddiastolic
velocities in the short posterior ciliary artery (fig. 2 and 3).
All other parameters assessed by CDI measurements in the
Intraocular pressure changes Figure 1
Intraocular pressure changes. Intraocular pressure (IOP) at first and second examination. IOP was an observational param-
eter and was not subjected to statistical testing.BMC Ophthalmology 2005, 5:6 http://www.biomedcentral.com/1471-2415/5/6
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central retinal artery, short and long posterior ciliary
arteries and ophthalmic artery appeared to be stable.
Table 1 gives a detailed overview of the quantitative
results obtained by CDI before and after treatment with
latanoprost and table 2 does this for bimatoprost. In the
negative control group all parameters were stable over
time (table 3). Dorzolamide lead to a significant accelera-
tion of systolic blood flow in the short posterior ciliary
artery (table 4).
Discussion
Based on the presented results bimatoprost or latanoprost
and have no significant influence on hemodynamics in
the short posterior ciliary artery has to be rejected,
although a tendency toward improved peak systolic and
end diastolic blood flow velocities was detected in both
treatment groups compared with the negative control
group.
To our knowledge the present study is the first to directly
compare hemodynamic effects of bimatoprost and latan-
oprost in patients with normal tension glaucoma. An
altered blood flow velocity due to a vasoconstricting activ-
ity of bimatoprost reported from Allemann and col-
leagues[29] is not detectable in humans by CDI
measurements. These differences might be explained by
the in vitro system used by Allemann, who worked with
isolated ciliary arteries from pigs. Apart from potential dif-
ferences between species, the balance between neuronal,
endothelial and myogenic influences on vascular tone is
Peak systolic velocity Figure 2
Peak systolic velocity. Peak systolic velocity (PSV) at first and second examination. In tendency, both compounds led to a 
slight increase of PSV, which was statistically not significant. Dorzolamide led to a statistical increase of PSV.BMC Ophthalmology 2005, 5:6 http://www.biomedcentral.com/1471-2415/5/6
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disturbed in such an in vitro setting. In vitro studies for
latanoprost revealed minimal vasoactivity.[28] The chem-
ical origin of latanoprost is the prostaglandin PGF2α ,
which increases arterial tone. [25-27] Bimatoprost is a
derivative of the prostamide F2α , which is enzymatically
formed from PGF2α  and should act similar like PGF2α , but
has a lower receptor affinity.[32] How vasoconstriction
influences ocular perfusion depends on its site of action:
Constriction of pre-capillary sphincters will cause a dete-
rioration of blood flow. On the other hand, moderate
constriction of the entire arterial system of an organ will
increase perfusion pressure. From this theoretic view pros-
taglandins could influence ocular blood flow in positive
and negative direction or both effects neutralize each
other.
For latanoprost a handful of studies dealing with its effects
on ocular perfusion have been published. Some of these
studies state positive effects.[13,33,34] All these studies
have in common that acute and short-term effects from
less than an hour up to one week after application of the
drug were observed. In accordance with the present
results, studies with an extended follow up did not find
any mid- or long-term effect of latanoprost on ocular
hemodynamics.[13,35,36] A possible explanation for the
difference between long- and short-term effects might be
the acute reduction of intraocular pressure, which will
End diastolic velocity Figure 3
End diastolic velocity. End-diastolic velocity (EDV) at first and second examination. In tendency, both compounds led to a 
slight increase of EDV, which was statistically not significant.BMC Ophthalmology 2005, 5:6 http://www.biomedcentral.com/1471-2415/5/6
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result in an increased ocular perfusion pressure and leads
to an improvement of ocular hemodynamics. For compar-
ison with the presented results one has to point out that
the previous reports were carried out with patients suffer-
ing from primary open angle glaucoma with initially
increased IOP. Thus it is difficult to differentiate whether
the observed improvement of ocular perfusion can be
attributed to a primary effect of the active agent on the
ocular vasculature or is secondary to IOP-reduction. In the
setting of the present study the absolute IOP reduction in
relation to ocular perfusion pressure is low and does affect
ocular perfusion pressure only by approximately 5%. Ret-
robulbar blood flow velocities are directly proportional to
ocular perfusion pressure. Subsequently, the effect of such
a change in intraocular pressure on retrobulbar blood
flow velocities is low, particularly compared to the
changes seen after the administration of dorzolamide.
Nevertheless, the tendency of an increase of retrobulbar
blood flow velocity is visible in all treated groups.
Patients with normal tension glaucoma are therefore a
particularly interesting group for the clinical investigation
of hemodynamic effects of antiglaucomatous eye drops
since results are less skewed by changes in IOP. In addi-
Table 1: Influence of bimatoprost on retrobulbar hemodynamics. Influence of bimatoprost on ocular perfusion. Overview of the results 
from CDI measurements before and one month after regular application of bimatoprost: Increase of blood flow velocities were 
statistically not significant (n = 11). Bold printed measures were subjected to statistical testing; all other parameters were 
observational only.
PSV (cms-1) EDV (cms-1)R I P I
OA before bimatoprost 31.6 ± 3.5 3.5 ± 0.9 0.89 ± 0.02 2.76 ± 0.20
after bimatoprost 38.5 ± 4.8 4.2 ± 0.7 0.87 ± 0.03 2.53 ± 0.21
CRA before bimatoprost 7.9 ± 0.9 1.4 ± 0.2 0.79 ± 0.04 2.22 ± 0.31
after bimatoprost 8.1 ± 0.5 1.7 ± 0.1 0.79 ± 0.02 1.90 ± 0.10
SPCA before bimatoprost 8.0 ± 1.1 1.9 ± 0.1 0.71 ± 0.03 1.61 ± 0.15
after bimatoprost 10.1 ± 1.2 2.8 ± 0.4 0.75 ± 0.01 1.66 ± 0.05
LPCA before bimatoprost 14.8 ± 3.0 3.0 ± 0.7 0.78 ± 0.03 1.90 ± 0.17
after bimatoprost 16.8 ± 2.2 3.0 ± 0.3 0.80 ± 0.02 1.90 ± 0.12
Abbreviations: OA – Ophthalmic artery, CRA – central retinal artery, SPCA – short posterior ciliary artery, LPCA – long posterior ciliary artery, 
PSV – peak systolic velocity, EDV – enddiastolic velocity, RI – resistive index, PI – pulsatility index.
Table 2: Influence of latanoprost on retrobulbar hemodynamics. Influence of latanoprost on ocular perfusion. Overview of the results 
from CDI measurements before and one month after regular application of latanoprost: Increase of blood flow velocities were 
statistically not significant (n = 10). Bold printed measures were subjected to statistical testing; all other parameters were 
observational only.
PSV (cms-1) EDV (cms-1)R I P I
OA before latanoprost 31.7 ± 3.1 4.6 ± 0.9 0.87 ± 0.02 2.59 ± 0.15
after latanoprost 39.0 ± 10.1 6.2 ± 1.2 0.83 ± 0.01 2.14 ± 0.09
CRA before latanoprost 7.6 ± 0.6 1.5 ± 0.1 0.78 ± 0.01 1.96 ± 0.10
after latanoprost 8.4 ± 0.9 1.7 ± 0.1 0.79 ± 0.02 1.95 ± 0.13
SPCA before latanoprost 8.6 ± 1.8 1.8 ± 0.2 0.74 ± 0.03 1.75 ± 0.13
after latanoprost 9.5 ± 1.1 2.5 ± 0.4 0.73 ± 0.03 1.60 ± 0.11
LPCA before latanoprost 13.1 ± 1.5 2.5 ± 0.3 0.81 ± 0.02 1.96 ± 0.14
after latanoprost 13.0 ± 1.9 2.5 ± 0.4 0.78 ± 0.04 1.90 ± 0.21
Abbreviations: OA – Ophthalmic artery, CRA – central retinal artery, SPCA – short posterior ciliary artery, LPCA – long posterior ciliary artery, 
PSV – peak systolic velocity, EDV – enddiastolic velocity, RI – resistive index, PI – pulsatility index.BMC Ophthalmology 2005, 5:6 http://www.biomedcentral.com/1471-2415/5/6
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tion, a reduction in ocular perfusion might play a major
role in the pathogenesis of normal tension glaucoma.[37]
Reversal of this condition could be of great clinical benefit
for this patient group and deterioration of ocular per-
fusion is expected to accelerate progression of glaucoma-
tous optic neuropathy. Therefore normal tension
glaucoma requires a therapy which ideally improves
hemodynamics of the eye, but at least does not alter it in
a negative way.
Although not primary end-point of the present study, the
results indicate that latanoprost and bimatoprost have the
capability to reduce IOP in patients with normal tension
glaucoma, despite the fact that initial IOP levels before the
treatment are low. Relative IOP-reduction in the present
study is smaller with previous reports on treatment of
patients with primary open angle glaucoma.[22,38,39]
This is most likely due to the low initial intraocular pres-
sure in the patient population with normal tension glau-
coma. Studies on the IOP-lowering effect of
Table 3: Influence of dorzolamide on retrobulbar hemodynamics. Ocular perfusion in the dorzolamide group. CDI measurements 
obtained from the patient group treated with dorzolamide (n = 12). The time period between between first and second measurement 
was 3–5 weeks. Data are given as mean ± standard deviation. Bold printed measures were subjected to statistical testing; all other 
parameters were observational only.
PSV (cms-1) EDV (cms-1)R I P I
OA before dorzolamide 29.6 ± 1.2 3.3 ± 0.4 0.89 ± 0.02 2.82 ± 0.25
after dorzolamide 37.2 ± 3.5 4.4 ± 0.7 0.88 ± 0.02 2.64 ± 0.20
CRA before dorzolamide 7.3 ± 0.8 1.4 ± 0.1 0.80 ± 0.02 1.98 ± 0.18
after dorzolamide 8.5 ± 0.8 1.8 ± 0.2 0.78 ± 0.02 1.97 ± 0.24
SPCA before dorzolamide 8.5 ± 0.8 1.9 ± 0.2 0.77 ± 0.02 1.79 ± 0.11
after dorzolamide 12.8 ± 1.4 * 2.2 ± 0.2 0.80 ± 0.03 1.91 ± 0.13
LPCA before dorzolamide 10.9 ± 0.8 2.0 ± 0.3 0.73 ± 0.07 1.80 ± 0.22
after dorzolamide 16.9 ± 1.7 2.9 ± 0.3 0.83 ± 0.01 1.95 ± 0.12
Asterisk (*) denotes statistic significance (P < 0.006). Abbreviations: OA – Ophthalmic artery, CRA – central retinal artery, SPCA – short posterior 
ciliary artery, LPCA – long posterior ciliary artery, PSV – peak systolic velocity, EDV – enddiastolic velocity, RI – resistive index, PI – pulsatility 
index.
Table 4: CDI measurements in the control group. Ocular perfusion in the control group. CDI measurements obtained from the 
control group (n = 8). The time period between between first and second measurement was 3–5 weeks. Local and systemic medication 
was not changed between the two examinations of the patient. Data are given as mean ± standard deviation. Bold printed measures 
were subjected to statistical testing; all other parameters were observational only.
PSV (cms-1) EDV (cms-1)R I P I
OA first examination 29.3 ± 2.6 3.7 ± 0.6 0.87 ± 0.02 2.57 ± 0.29
second examination 30.6 ± 3.2 5.4 ± 1.0 0.83 ± 0.02 2.08 ± 0.20
CRA first examination 8.2 ± 1.5 1.8 ± 0.4 0.76 ± 0.03 1.93 ± 0.19
second examination 7.5 ± 0.9 1.4 ± 0.1 0.80 ± 0.03 2.14 ± 0.21
SPCA first examination 10.8 ± 1.6 2.6 ± 0.5 0.75 ± 0.02 1.76 ± 0.17
second examination 10.1 ± 2.4 2.5 ± 0.6 0.75 ± 0.02 1.55 ± 0.09
LPCA first examination 18.0 ± 3.8 3.1 ± 0.8 0.82 ± 0.04 2.01 ± 0.21
second examination 18.0 ± 4.0 3.6 ± 0.9 0.77 ± 0.01 1.69 ± 0.12
Abbreviations: OA – Ophthalmic artery, CRA – central retinal artery, SPCA – short posterior ciliary artery, LPCA – long posterior ciliary artery, 
PSV – peak systolic velocity, EDV – enddiastolic velocity, RI – resistive index, PI – pulsatility index.BMC Ophthalmology 2005, 5:6 http://www.biomedcentral.com/1471-2415/5/6
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prostaglandins, predominantly latanoprost, in normal
tension glaucoma find an IOP-reduction in a similar mag-
nitude. [40-42] This can be taken as an indicator for good
compliance of the patients and it can be concluded that
both tested compounds have the capability to reliably
decrease IOP even in the lower range.
Some ophthalmologists doubt the reliability of CDI, but
the reliability of the CDI method has repeatedly been
shown in vitro[4] and in vivo[43]. Experiments performed
by our group are in accordance with these findings.[44]
The positive control with dorzolamide in the present
study underlines the applicability of CDI for assessing
pharmacological effects on ocular perfusion. To resolve
the potential problem of investigator dependency both
CDI-examinations for each patient were performed by the
same investigator. In addition, the CDI procedure was
performed in a highly standardized manner in our labora-
tory minimizing investigator dependency of the results.
The precise and clinically relevant evaluation of ocular
perfusion still poses a great challenge. Quantitative deter-
mination of total ocular blood flow with a single method
is not possible, but combination of different methods is
proposed to give a better approximation.[45] This fact
limits the explanatory power of this and other studies
addressing ocular perfusion in ophthalmological diseases.
Aim of the present study was to focus on glaucoma
patients and it is hypothesized that glaucoma is associated
with a localized disturbance of ocular hemodynamics at
the optic disc. The optic disc is supplied with blood by the
posterior ciliary arteries. The most reliable method for
evaluation of hemodynamics in the short posterior ciliary
artery is color Doppler imaging. Blood flow velocity in the
short posterior ciliary arteries is influenced on the one
hand by the vascular tone of the vessel itself but also by
the resistance of the dependent downstream vasculature.
Thus blood flow velocities in the short posterior ciliary
artery reflect also the hemodynamics at the level of the
optic disc. The influence of the tested compounds on per-
fusion of the entire eye cannot be answered by the present
study.
Recently it has been shown that the correlation between
measurements of ocular hemodynamics with different
methodologies is limited.[30] Thus differences in out-
come between studies investigating the effects of the same
compound on ocular perfusion might at least partially be
explained by the variability between the methodologies.
Color Doppler imaging (CDI) measures blood flow veloc-
ities. Measurement of ocular blood flow by the method of
Langham (LOBF) is based on assessing pulse synchronal
oscillations of the IOP and calculate ocular perfusion
from its amplitude by mathematical algorithms.[46]
From the parameter determined by CDI only the pulsatil-
ity index correlates with the perfusion index determined
by LOBF.[30] Therefore the comparison of the results of
the present study e.g. with the work by Georgopoulus et
al.[33] is limited.
Conclusion
In summary no significant influence of latanoprost and
bimatoprost on ocular hemodynamics was detected in the
present study. In accordance with previous reports
dorzolamide led to an increase of blood flow velocity in
systole. A suitable compound for the treatment of normal
tension glaucoma should at least act hemodynamically
neutral. This minimum requirement is fulfilled by all
three tested compounds. Only dorzolamide was capable
to improve perfusion in the posterior ciliary arteries.
When comparing both prostaglandin-like eye drops, they
showed similar effects on ocular hemodynamics and IOP.
Subsequently latanoprost and bimatoprost can be consid-
ered as equivalent in the treatment of normal tension
glaucoma. However, in order to comprehensively treat the
pathogenic disturbances leading or at least contributing to
normal tension glaucoma there is still a great demand for
a pharmacological compound which significantly
enhances perfusion of the optic nerve head.
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